•
Sep 30, 2024

Quanterix Q3 2024 Earnings Report

Quanterix reported preliminary financial results and reaffirmed its full year 2024 guidance.

Key Takeaways

Quanterix announced preliminary financial results for Q3 2024, achieving its sixth consecutive quarter of double-digit growth with a revenue of $35.7 million, a 13% increase compared to the prior year, and reaffirmed its full year 2024 revenue guidance of $134 million to $138 million. The company also disclosed the need to restate certain prior period financial statements.

Revenue of $35.7 million, a 13% increase compared to the corresponding prior year period.

GAAP gross margin of 58.9% and Non-GAAP gross margin of 53.4%.

Net cash usage in the quarter was $3.3 million.

Launched LucentAD Complete, a multi-marker test for Alzheimer’s Disease (AD) detection.

Total Revenue
$35.8M
Previous year: $31.3M
+14.3%
EPS
-$0.19
Previous year: -$0.21
-9.5%
Gross Profit
$21.1M
Previous year: $17.8M
+18.7%
Cash and Equivalents
$296M
Previous year: $201M
+47.1%
Free Cash Flow
-$6.6M
Previous year: -$4.84M
+36.4%
Total Assets
$411M
Previous year: $429M
-4.2%

Quanterix

Quanterix

Forward Guidance

The Company reaffirms its 2024 revenue guidance range of $134 million to $138 million. The Company continues to expect GAAP gross margin percentage to be in the range of 57%-61%, and non-GAAP gross margin percentage to be in the range of 51%-55%. The Company continues to anticipate 2024 cash usage to be approximately $30 million.